Drugs
In this section you will find Drugs market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
-
Breast Cancer Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 331 companies plus partners who are today developing 450 drugs targeting breast cancer in development. across 229 different targets. In addition, there are 5 suspended drugs and another 182 drugs where development has been ceased. Learn More -
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 187 companies plus partners who are today developing 245 IL-2 pathway targeting drugs in 698 developmental projects in cancer across 127 different targets. In addition, there are 4 suspended drugs and another 104 drugs where development has been ceased. Learn More -
Ovarian Cancer Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 212 companies plus partners who are today developing 286 drugs targeting ovarian cancer in development. across 196 different targets. In addition, there are 7 suspended drugs and another 83 drugs where development has been ceased. Learn More -
RNA Interference Therapy in Oncology Drug Pipeline Update 2012
$1,370.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 43 companies plus partners who are today developing 58 RNA interference drugs in 75 developmental projects in cancer across 44 different targets. In addition, another 23 drugs where development has been ceased. Learn More -
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 197 companies plus partners who are today developing 221 T cell receptor pathway targeting drugs in 731 developmental projects in cancer across 130 different targets. In addition, there are 7 suspended drugs and another 129 drugs where development has been ceased. Learn More -
Bladder Cancer Drug Pipeline Update 2012
$1,370.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 93 companies plus partners who are today developing 103 drugs targeting bladder cancer in development. across 73 different targets. In addition, there are 3 suspended drugs and another 29 drugs where development has been ceased. Learn More -
Gene Therapy in Oncology Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 116 companies plus partners who are today developing 104 gene therapy drugs in 246 developmental projects in cancer across 88 different targets. In addition, there are 4 suspended drugs and another 94 drugs where development has been ceased. Learn More -
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 144 companies plus partners who are today developing 203 Kit receptor pathway targeting drugs in 694 developmental projects in cancer across 114 different targets. In addition, there are 2 suspended drugs and another 94 drugs where development has been ceased. Learn More -
Prostate Cancer Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 324 companies plus partners who are today developing 394 drugs targeting prostate cancer in development. across 227 different targets. In addition, there are 5 suspended drugs and another 164 drugs where development has been ceased. Learn More -
Head and Neck Cancer Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 123 companies plus partners who are today developing 133 drugs targeting head and neck cancer in development. across 108 different targets. In addition, there is 1 suspended drug and another 40 drugs where development has been ceased. Learn More -
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2012
$1,370.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 89 companies plus partners who are today developing 88 Wnt pathway targeting drugs in 273 developmental projects in cancer across 97 different targets. In addition, there is 1 suspended drug and another 45 drugs where development has been ceased. Learn More -
Hematological Cancers Drug Pipeline Update 2012
$2,750.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 374 companies plus partners who are today developing 584 hematological cancer drugs in 1169 developmental projects in cancer across 300 different targets. In addition, there are 7 suspended drugs and another 184 drugs where development has been ceased. Learn More -
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2012
$685.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 40 companies plus partners who are today developing 31 Hedgehog pathway targeting drugs in 123 developmental projects in cancer across 40 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More -
Immunotherapy in Oncology Drug Pipeline Update 2012
$3,450.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 469 companies plus partners who are today developing 871 cancer immunotherapy drugs in 1970 developmental projects in cancer across 337 different targets. In addition, there are 16 suspended drugs and another 343 drugs where development has been ceased. Learn More -
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 207 companies plus partners who are today developing 264 Alpha6Beta4 integrin pathway targeting drugs in 848 developmental projects in cancer across 107 different targets. In addition, there is 1 suspended drug and another 125 drugs where development has been ceased. Learn More
Drugs
In this section you will find Drugs market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
-
Breast Cancer Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 331 companies plus partners who are today developing 450 drugs targeting breast cancer in development. across 229 different targets. In addition, there are 5 suspended drugs and another 182 drugs where development has been ceased. Learn More -
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 187 companies plus partners who are today developing 245 IL-2 pathway targeting drugs in 698 developmental projects in cancer across 127 different targets. In addition, there are 4 suspended drugs and another 104 drugs where development has been ceased. Learn More -
Ovarian Cancer Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 212 companies plus partners who are today developing 286 drugs targeting ovarian cancer in development. across 196 different targets. In addition, there are 7 suspended drugs and another 83 drugs where development has been ceased. Learn More -
RNA Interference Therapy in Oncology Drug Pipeline Update 2012
$1,370.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 43 companies plus partners who are today developing 58 RNA interference drugs in 75 developmental projects in cancer across 44 different targets. In addition, another 23 drugs where development has been ceased. Learn More -
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 197 companies plus partners who are today developing 221 T cell receptor pathway targeting drugs in 731 developmental projects in cancer across 130 different targets. In addition, there are 7 suspended drugs and another 129 drugs where development has been ceased. Learn More -
Bladder Cancer Drug Pipeline Update 2012
$1,370.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 93 companies plus partners who are today developing 103 drugs targeting bladder cancer in development. across 73 different targets. In addition, there are 3 suspended drugs and another 29 drugs where development has been ceased. Learn More -
Gene Therapy in Oncology Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 116 companies plus partners who are today developing 104 gene therapy drugs in 246 developmental projects in cancer across 88 different targets. In addition, there are 4 suspended drugs and another 94 drugs where development has been ceased. Learn More -
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 144 companies plus partners who are today developing 203 Kit receptor pathway targeting drugs in 694 developmental projects in cancer across 114 different targets. In addition, there are 2 suspended drugs and another 94 drugs where development has been ceased. Learn More -
Prostate Cancer Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 324 companies plus partners who are today developing 394 drugs targeting prostate cancer in development. across 227 different targets. In addition, there are 5 suspended drugs and another 164 drugs where development has been ceased. Learn More -
Head and Neck Cancer Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 123 companies plus partners who are today developing 133 drugs targeting head and neck cancer in development. across 108 different targets. In addition, there is 1 suspended drug and another 40 drugs where development has been ceased. Learn More -
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2012
$1,370.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 89 companies plus partners who are today developing 88 Wnt pathway targeting drugs in 273 developmental projects in cancer across 97 different targets. In addition, there is 1 suspended drug and another 45 drugs where development has been ceased. Learn More -
Hematological Cancers Drug Pipeline Update 2012
$2,750.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 374 companies plus partners who are today developing 584 hematological cancer drugs in 1169 developmental projects in cancer across 300 different targets. In addition, there are 7 suspended drugs and another 184 drugs where development has been ceased. Learn More -
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2012
$685.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 40 companies plus partners who are today developing 31 Hedgehog pathway targeting drugs in 123 developmental projects in cancer across 40 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More -
Immunotherapy in Oncology Drug Pipeline Update 2012
$3,450.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 469 companies plus partners who are today developing 871 cancer immunotherapy drugs in 1970 developmental projects in cancer across 337 different targets. In addition, there are 16 suspended drugs and another 343 drugs where development has been ceased. Learn More -
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2012
$2,050.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 207 companies plus partners who are today developing 264 Alpha6Beta4 integrin pathway targeting drugs in 848 developmental projects in cancer across 107 different targets. In addition, there is 1 suspended drug and another 125 drugs where development has been ceased. Learn More